Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine
Sandhya Sharma and Rayne H. Rouce
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital, Houston, Texas, USA. Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Address correspondence to: Rayne H. Rouce, 1102 Bates Street, Suite 1770, Houston, Texas 77030, USA. Phone: 832.824.4723; Email: rhrouce@txch.org.
Find articles by
Sharma, S.
in:
JCI
|
PubMed
|
Google Scholar
|
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital, Houston, Texas, USA. Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
Address correspondence to: Rayne H. Rouce, 1102 Bates Street, Suite 1770, Houston, Texas 77030, USA. Phone: 832.824.4723; Email: rhrouce@txch.org.
Find articles by Rouce, R. in: JCI | PubMed | Google Scholar
First published April 15, 2019 - More info
J Clin Invest. 2019;129(5):1836–1838. https://doi.org/10.1172/JCI128370.
© 2019 American Society for Clinical Investigation
The Epstein-Barr virus (EBV) is estimated to infect a large part of the population and is associated with a variety of human tumors; therefore, EBV is an important target for vaccine development. In this issue of the JCI, Rühl et al. developed a promising heterologous prime-boost vaccination strategy for EBV-associated malignancies and symptomatic primary infection. The authors show that two prime-boost regimens, using either dendritic cells or an adenovirus approach targeting nuclear antigen EBNA1 followed by a modified vaccinia virus Ankara (MVA) booster, induced significant T cell–mediated, EBV-specific immune control and Ab production. These findings suggest that administration of heterologous prime-boost vaccinations targeting EBNA1 may result in potent CD4+ and CD8+ T cell–mediated EBV immune control and may be a promising clinical approach.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)